Abstract:Receptor activator of NF-κB ligand (RANKL) plays a key role in osteoclast-induced bone resorption across a range of degenerative bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal osteoporosis at high or increased risk of fracture in the United States and globally. In the present study, we generated transgenic mice (TghuRANKL) carrying the human RANKL (huRANKL) genomic region and achieved a physiologically relevant pattern of RANKL overexpression in order to establish novel genetic models for assessing skeletal and extraskeletal pathologies associated with excessive RANKL and for testing clinical therapeutic candidates that inhibit human RANKL. TghuRANKL mice of both sexes developed early-onset bone loss, and the levels of huRANKL expression were correlated with bone resorption and disease severity. Low copy Tg5516 mice expressing huRANKL at low levels displayed a mild osteoporotic phenotype as shown by trabecular bone loss and reduced biomechanical properties. Notably, overexpression of huRANKL, in the medium copy Tg5519 line, resulted in severe early-onset osteoporosis characterized by lack of trabecular bone, destruction of the growth plate, increased osteoclastogenesis, bone marrow adiposity, increased bone remodeling, and severe cortical bone porosity accompanied by decreased bone strength. An even more severe skeletal phenotype developed in the high copy Tg5520 founder with extensive soft tissue calcification. Model validation was further established by evidence that denosumab, an antibody that inhibits human but not murine RANKL, fully corrected the hyper-resorptive and osteoporotic phenotypes of Tg5519 mice. Furthermore, overexpression of huRANKL rescued osteopetrotic phenotypes of RANKL-defective mice. These novel huRANKL transgenic models of osteoporosis represent an important advance for understanding the pathogenesis and treatment of high-turnover bone diseases and other disease states caused by excessive RANKL.

Heterologous expression, purification and function of the extracellular domain of human RANK

A statistical approach for optimization of RANKL overexpression in Escherichia coli: purification and characterization of the protein

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

Structural and Functional Insights of RANKL-RANK Interaction and Signaling.

Cloning, Sequencing, and Functional Characterization of the Rat Homologue of Receptor Activator of NF‐κB Ligand

Crystallization and Preliminary X-Ray Analysis of Mouse Rank and Its Complex with Rankl

Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (Rankl)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.

The Affinity of Human Rank Binding to Its Ligand Rankl

Recombinant Soluble Receptor Activator of Nuclear Factor-Kappab Inhibits Parathyroid Hormone-Induced Osteoclastogenesis in Vitro.

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Functional Identification Of Three Receptor Activator Of Nf-Kappa B Cytoplasmic Motifs Mediating Osteoclast Differentiation And Function

Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.

Cloning, Expression and Bioactivity of Chicken Receptor Activator of NF-κB Ligand (Chrankl)

Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin.

Inhibition of Osteoclastogenesis by RNA Interference Targeting RANK

Cloning,Expression and Bioactivity Analysis of the Active Domain of the Mouse Receptor Activator of NF-κB Ligand

Murine Rank Protein'S Inhibition of Bone Resorption

Expression , Purification and Biological Characterization of the Extracellular Domain of CD 40 from Pichia Pastoris

Construction of TNFR1/RANK Chimera and Its Significance in Study of Differentiation in Osteoclast

Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation